Extensive-stage SCLC
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) (NCT07744256) | Beijing Biotech | 2026-03-02 |
Track Extensive-stage SCLC automatically
Every clearance here is in the API, with alerts when new ones post.